Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MED
MED logo

MED Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Medifast Inc (MED) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
11.040
1 Day change
-1.87%
52 Week Range
15.460
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Medifast Inc (MED) is not a strong buy at this time for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators suggest the stock is oversold, but the lack of positive catalysts, weak trading sentiment, and absence of recent financial or valuation data make it difficult to justify an immediate purchase.

Technical Analysis

The MACD histogram is -0.188 and negatively expanding, indicating bearish momentum. The RSI_6 at 13.055 signals the stock is oversold, which may suggest a potential rebound. However, moving averages are converging, showing no clear trend. Key support is at 11.199, and resistance is at 12.261.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
11
Buy
5

Positive Catalysts

  • The RSI indicates the stock is oversold, which could attract buyers. Historical patterns suggest a 4.52% chance of positive movement in the next month.

Neutral/Negative Catalysts

  • No significant news, hedge fund, or insider activity. The MACD and moving averages show bearish momentum. Lack of recent financial data or valuation insights.

Financial Performance

No recent financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Wall Street analysts forecast MED stock price to rise
Analyst Rating
0
Wall Street analysts forecast MED stock price to rise
Buy
Hold
Sell
0
Current: 11.250
sliders
Low
0
Averages
0
High
0
0
Current: 11.250
sliders
Low
0
Averages
0
High
0
Stephens
Stephens
Equal Weight
downgrade
$15 -> $12
AI Analysis
2026-02-19
Reason
Stephens
Stephens
Price Target
$15 -> $12
AI Analysis
2026-02-19
downgrade
Equal Weight
Reason
Stephens lowered the firm's price target on Medifast to $12 from $15 and keeps an Equal Weight rating on the shares. While the firm believes that operating discipline and restructuring savings are important, the "key proof point will be a return to growth in the coach count," the analyst tells investors in a post-earnings note.

People Also Watch